|Bid||37.860 x 900|
|Ask||37.870 x 1400|
|Day's Range||37.100 - 37.860|
|52 Week Range||30.690 - 47.820|
|PE Ratio (TTM)||43.60|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.84|
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from the companies' Phase 3 clinical program for YUPELRI™ (revefenacin) inhalation solution were featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, which is being held in Paris, France on September 15-19, 2018. Presented data showed reductions in the rates of chronic obstructive pulmonary disease (COPD) exacerbations ranging from 15% to 18% in moderate to very severe COPD patients administered once-daily YUPELRI for up to 52 weeks as compared to placebo and tiotropium (Spiriva® HandiHaler®). While the YUPELRI Phase 3 program was not designed or powered to achieve statistical significance on differences in COPD exacerbation rates, researchers were interested in a post-hoc analysis of data from the studies to identify trends in this area.
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.
On September 12, Johnson & Johnson (JNJ) stock closed at $139.36. That was a 0.61% rise from the previous day’s closing price of $138.51. Currently, JNJ stock is trading above its 50-day moving average of $133.29 and below its 200-day moving average of $127.99.
- Esmolol Hydrochloride in Sodium Chloride Injection is used to control heart rate - HERTFORDSHIRE, England and PITTSBURGH , Sept. 13, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: ...
Johnson & Johnson (JNJ) is one of the major healthcare companies in the world. It operates through its pharmaceuticals, medical devices, and consumer business segments. Although its pharmaceutical business generates most of its sales, medical devices and consumer business include a number of leading brands in their respective market spaces.
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that new data from the Phase 3 YUPELRI™ (revefenacin) inhalation solution clinical program will be featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, being held in Paris, France on September 15-19, 2018. The presented data will highlight chronic obstructive pulmonary disease (COPD) exacerbation rates observed in the Phase 3 clinical program of YUPELRI in patients with moderate to very severe COPD.
Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra
Generic-drug and biotech stocks plunged into the red Thursday after several leading hospital groups launched a nonprofit to undercut drug prices.
U.S. drugstore chain Walgreens Boots Alliance Inc said on Thursday emergency allergy shots from Kaleo will be available in its stores, the latest effort to address shortages of the lifesaving treatment during the back-to-school season. There has been an acute shortage of Mylan's EpiPen, which dominates the allergy market, with the health regulator last month extending the expiration date of specific lots of the treatment. In August, Mylan issued a warning that the devices may not always be available.
The biotech sector performed well in August, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) up almost 3.5% this week alone. Research by Raymond James indicates that in just the past week, biotech ...
Parents are scrambling to find pharmacies carrying EpiPens for the new school year as regulators and the drug’s manufacturer struggle to abate a continuing global shortage of the lifesaving devices. EpiPens, the emergency epinephrine treatment for allergic reactions, have been in short supply since at least May, when the U.S. Food and Drug Administration first declared a shortage. A rival epinephrine injector product, a generic version of Adrenaclick made by Amneal Pharmaceuticals Inc., is also in short supply, according to the FDA.
Only after calling between eight and 10 pharmacies in her New Jersey area was Wachtler able to find a two-pack of the generic EpiPen—and it was the pharmacy’s last box. Mylan’s (MYL) brand-name EpiPen and the authorized generic, two widely used allergic reaction treatments, as well as Amneal Pharmaceuticals’ (AMRX) generic auto-injector Adrenaclick were added to the Food and Drug Administration’s drug shortage list in May.
A popular exchange-traded fund that tracks the health-care sector finished at its highest level in its history on Friday. The Health Care Select Sector SPDR ETF (XLV) advanced by 0.4% to reach 91.82, representing its highest level since the vehicle was created in 1998 to match the S&P 500 index's (SPX) health-care sector. The record for the health-care ETF underscores a rally on Wall Street in late August that has the small-capitalization Russell 2000 index (RUT) the Nasdaq Composite Index (COMP) and the S&P 500 putting records of their own.
When Teva Pharmaceutical Industries Ltd.'s (TEVA) generic version of the EpiPen allergic reaction treatment was approved last week, amid spot shortages of the branded product and concerns about allergic children needing the products as they go back to school, the timing seemed perfect. While Labor Day is traditionally thought of as back-to-school season, schools in some parts of the country start as early as July, and elsewhere August is considered the new September, CNN has previously reported.
Mylan NV (MYL) shares rose 2.9% in Friday premarket trade after the company was upgraded to outperform by EvercoreISI analyst Umer Raffat on the strength of its pipeline of copycat biosimilar drugs and new product launches. Excitement about biosimilar drugs has been muted because they haven't sold well, but there's evidence that the competitive factors that have held them up may soon change, he said. Raffat was also hopeful about the company's upcoming product launches, including a branded chronic obstructive pulmonary disease therapy with a Food and Drug Administration approval decision expected in mid-November.
Teva Pharmaceutical (NYSE:TEVA) perfectly illustrates the dangers of trading volatile biotech stocks. Last year was particularly horrendous for TEVA stock. The company’s shares lost almost half their market value.
On August 22, Teva Pharmaceutical Industries (TEVA) fell 2.6% as compared to the previous day’s closing price. Over the last week, the company announced FDA (U.S. Food and Drug Administration) approval for its generic version of Mylan’s (MYL) EpiPen on August 16 and the release of positive data released on the same day from Fasinumab, which is being developed in collaboration with Regeneron Pharmaceuticals (REGN) for the treatment of osteoarthritis of the knee or hip. Plus, Berkshire Hathaway announced its portfolio holdings in the second quarter of fiscal 2018 last week, which showed that the company has further increased its stake in Teva Pharmaceutical.
The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment. The shortage has largely been due to ongoing manufacturing issues at a Pfizer plant which supplies EpiPens. EpiPen autoinjectors allow the patient or a caretaker to administer a dose of epinephrine in case of a severe allergic reaction, such as to bee stings or exposure to peanuts.